FT. WORTH, Texas--(BUSINESS WIRE)--Galderma Laboratories, L.P. today announced the publication of the long-term efficacy and safety results of a one-year, open-label, non-comparative study of Mirvaso® (brimonidine) Topical Gel, 0.33%* in patients with moderate to severe facial erythema (redness) of rosacea. Mirvaso was approved by the U.S. Food and Drug Administration in August 2013 as the first and only topical treatment indicated for the persistent facial erythema of rosacea in adults 18 years of age or older.1 The results of this study, in which 276 subjects applied Mirvaso for at least one year, demonstrate that Mirvaso is safe and effective when used once-daily for up to 12 months.2 The study results were published in the January issue of Journal of Drugs in Dermatology.
Help employers find you! Check out all the jobs and post your resume.
